

DANIELA REIS JOAQUIM DE FREITAS
(ORGANIZADORA)

AGENDA
GLOBAL

DE PESQUISA

EM CIÊNCIAS

BIOLÓGICAS

Atena
Editora
Ano 2021

DANIELA REIS JOAQUIM DE FREITAS
(ORGANIZADORA)

AGENDA
GLOBAL

DE PESQUISA

EM CIÊNCIAS

Biológicas

Atena
Editora
Ano 2021

Editora chefe

Profª Drª Antonella Carvalho de Oliveira

Editora executiva

Natalia Oliveira

Assistente editorial

Flávia Roberta Barão

Bibliotecária

Janaina Ramos

Projeto gráfico

Camila Alves de Cremo

Daphynny Pamplona

Luiza Alves Batista

Maria Alice Pinheiro

Natália Sandrini de Azevedo

Imagens da capa

iStock

Edição de arte

Luiza Alves Batista

2021 by Atena Editora

Copyright © Atena Editora

Copyright do texto © 2021 Os autores

Copyright da edição © 2021 Atena Editora

Direitos para esta edição cedidos à Atena Editora pelos autores.

Open access publication by Atena Editora



Todo o conteúdo deste livro está licenciado sob uma Licença de Atribuição *Creative Commons*. Atribuição-Não-Comercial-NãoDerivativos 4.0 Internacional (CC BY-NC-ND 4.0).

O conteúdo dos artigos e seus dados em sua forma, correção e confiabilidade são de responsabilidade exclusiva dos autores, inclusive não representam necessariamente a posição oficial da Atena Editora. Permitido o *download* da obra e o compartilhamento desde que sejam atribuídos créditos aos autores, mas sem a possibilidade de alterá-la de nenhuma forma ou utilizá-la para fins comerciais.

Todos os manuscritos foram previamente submetidos à avaliação cega pelos pares, membros do Conselho Editorial desta Editora, tendo sido aprovados para a publicação com base em critérios de neutralidade e imparcialidade acadêmica.

A Atena Editora é comprometida em garantir a integridade editorial em todas as etapas do processo de publicação, evitando plágio, dados ou resultados fraudulentos e impedindo que interesses financeiros comprometam os padrões éticos da publicação. Situações suspeitas de má conduta científica serão investigadas sob o mais alto padrão de rigor acadêmico e ético.

Conselho Editorial**Ciências Biológicas e da Saúde**

Prof. Dr. André Ribeiro da Silva – Universidade de Brasília

Profª Drª Anelise Levay Murari – Universidade Federal de Pelotas

Prof. Dr. Benedito Rodrigues da Silva Neto – Universidade Federal de Goiás

Profª Drª Daniela Reis Joaquim de Freitas – Universidade Federal do Piauí

Profª Drª Débora Luana Ribeiro Pessoa – Universidade Federal do Maranhão

Prof. Dr. Douglas Siqueira de Almeida Chaves – Universidade Federal Rural do Rio de Janeiro

Prof. Dr. Edson da Silva – Universidade Federal dos Vales do Jequitinhonha e Mucuri
Profª Drª Elizabeth Cordeiro Fernandes – Faculdade Integrada Medicina
Profª Drª Eleuza Rodrigues Machado – Faculdade Anhanguera de Brasília
Profª Drª Elane Schwinden Prudêncio – Universidade Federal de Santa Catarina
Profª Drª Eysler Gonçalves Maia Brasil – Universidade da Integração Internacional da Lusofonia Afro-Brasileira
Prof. Dr. Ferlando Lima Santos – Universidade Federal do Recôncavo da Bahia
Profª Drª Fernanda Miguel de Andrade – Universidade Federal de Pernambuco
Prof. Dr. Fernando Mendes – Instituto Politécnico de Coimbra – Escola Superior de Saúde de Coimbra
Profª Drª Gabriela Vieira do Amaral – Universidade de Vassouras
Prof. Dr. Gianfábio Pimentel Franco – Universidade Federal de Santa Maria
Prof. Dr. Helio Franklin Rodrigues de Almeida – Universidade Federal de Rondônia
Profª Drª Iara Lúcia Tescarollo – Universidade São Francisco
Prof. Dr. Igor Luiz Vieira de Lima Santos – Universidade Federal de Campina Grande
Prof. Dr. Jefferson Thiago Souza – Universidade Estadual do Ceará
Prof. Dr. Jesus Rodrigues Lemos – Universidade Federal do Piauí
Prof. Dr. Jônatas de França Barros – Universidade Federal do Rio Grande do Norte
Prof. Dr. José Max Barbosa de Oliveira Junior – Universidade Federal do Oeste do Pará
Prof. Dr. Luís Paulo Souza e Souza – Universidade Federal do Amazonas
Profª Drª Magnólia de Araújo Campos – Universidade Federal de Campina Grande
Prof. Dr. Marcus Fernando da Silva Praxedes – Universidade Federal do Recôncavo da Bahia
Profª Drª Maria Tatiane Gonçalves Sá – Universidade do Estado do Pará
Profª Drª Mylena Andréa Oliveira Torres – Universidade Ceuma
Profª Drª Natiéli Piovesan – Instituto Federacão do Rio Grande do Norte
Prof. Dr. Paulo Inada – Universidade Estadual de Maringá
Prof. Dr. Rafael Henrique Silva – Hospital Universitário da Universidade Federal da Grande Dourados
Profª Drª Regiane Luz Carvalho – Centro Universitário das Faculdades Associadas de Ensino
Profª Drª Renata Mendes de Freitas – Universidade Federal de Juiz de Fora
Profª Drª Vanessa da Fontoura Custódio Monteiro – Universidade do Vale do Sapucaí
Profª Drª Vanessa Lima Gonçalves – Universidade Estadual de Ponta Grossa
Profª Drª Vanessa Bordin Viera – Universidade Federal de Campina Grande
Profª Drª Welma Emidio da Silva – Universidade Federal Rural de Pernambuco

Agenda global de pesquisa em ciências biológicas

Diagramação: Maria Alice Pinheiro
Correção: Mariane Aparecida Freitas
Indexação: Gabriel Motomu Teshima
Revisão: Os autores
Organizadora: Daniela Reis Joaquim de Freitas

Dados Internacionais de Catalogação na Publicação (CIP)

A265 Agenda global de pesquisa em ciências biológicas /
Organizadora Daniela Reis Joaquim de Freitas. – Ponta
Grossa - PR: Atena, 2021.

Formato: PDF

Requisitos de sistema: Adobe Acrobat Reader

Modo de acesso: World Wide Web

Inclui bibliografia

ISBN 978-65-5983-614-7

DOI: <https://doi.org/10.22533/at.ed.147210311>

1. Ciências biológicas. I. Freitas, Daniela Reis Joaquim
de (Organizadora). II. Título.

CDD 570

Elaborado por Bibliotecária Janaina Ramos – CRB-8/9166

Atena Editora

Ponta Grossa – Paraná – Brasil

Telefone: +55 (42) 3323-5493

www.atenaeditora.com.br

contato@atenaeditora.com.br

DECLARAÇÃO DOS AUTORES

Os autores desta obra: 1. Atestam não possuir qualquer interesse comercial que constitua um conflito de interesses em relação ao artigo científico publicado; 2. Declaram que participaram ativamente da construção dos respectivos manuscritos, preferencialmente na: a) Concepção do estudo, e/ou aquisição de dados, e/ou análise e interpretação de dados; b) Elaboração do artigo ou revisão com vistas a tornar o material intelectualmente relevante; c) Aprovação final do manuscrito para submissão.; 3. Certificam que os artigos científicos publicados estão completamente isentos de dados e/ou resultados fraudulentos; 4. Confirmam a citação e a referência correta de todos os dados e de interpretações de dados de outras pesquisas; 5. Reconhecem terem informado todas as fontes de financiamento recebidas para a consecução da pesquisa; 6. Autorizam a edição da obra, que incluem os registros de ficha catalográfica, ISBN, DOI e demais indexadores, projeto visual e criação de capa, diagramação de miolo, assim como lançamento e divulgação da mesma conforme critérios da Atena Editora.

DECLARAÇÃO DA EDITORA

A Atena Editora declara, para os devidos fins de direito, que: 1. A presente publicação constitui apenas transferência temporária dos direitos autorais, direito sobre a publicação, inclusive não constitui responsabilidade solidária na criação dos manuscritos publicados, nos termos previstos na Lei sobre direitos autorais (Lei 9610/98), no art. 184 do Código Penal e no art. 927 do Código Civil; 2. Autoriza e incentiva os autores a assinarem contratos com repositórios institucionais, com fins exclusivos de divulgação da obra, desde que com o devido reconhecimento de autoria e edição e sem qualquer finalidade comercial; 3. Todos os e-book são *open access*, desta forma não os comercializa em seu site, sites parceiros, plataformas de *e-commerce*, ou qualquer outro meio virtual ou físico, portanto, está isenta de repasses de direitos autorais aos autores; 4. Todos os membros do conselho editorial são doutores e vinculados a instituições de ensino superior públicas, conforme recomendação da CAPES para obtenção do Qualis livro; 5. Não cede, comercializa ou autoriza a utilização dos nomes e e-mails dos autores, bem como nenhum outro dado dos mesmos, para qualquer finalidade que não o escopo da divulgação desta obra.

APRESENTAÇÃO

A pesquisa não pode parar. Isto é um fato. E o livro “Agenda global de Pesquisa em Ciências Biológicas” é a prova de que o Brasil é profícuo quando se trata de pesquisa. Esta obra é composta por trabalhos científicos produzidos em diversas partes do país na forma de artigos originais e de revisão, que abordam desde o cultivo, triagem e citocompatibilidade de células-tronco mesenquimais expostas à nanotubos funcionalizados de carbono multicamadas até o controle de qualidade microbiológica do sururu (*Mytella falcata*) produzido no Rio de Janeiro, ou a análise temporal da disseminação de vegetação exótica em dunas do litoral do Rio Grande do Sul, ou o desenvolvimento do turismo e as mulheres erveiras da Amazônia. Todas estas pesquisas possuem campo dentro das Ciências Biológicas, mas fazem interface com meio Ambiente, Engenharia, Ciências da Saúde, Antropologia, Tecnologia de alimentos, entre outras áreas.

Ao longo de 13 capítulos serão discutidas diferentes temáticas, com embasamento teórico-científico adequado, atualizado e serão revistos conceitos importantes. Este livro é principalmente voltado para os estudantes e profissionais que desejam se aprofundar mais na pesquisa na grande área das Ciências Biológicas, com uma leitura rápida, dinâmica e cheia de possibilidades de aprendizado.

Assim como todas as publicações da Atena Editora, esta obra passou pela revisão de um Comitê de pesquisadores com mestrado e doutorado em programas de pós-graduação renomados no Brasil. Portanto, apresentamos ao leitor um trabalho de qualidade, atualizado e devidamente revisado por pares.

Boa leitura.


Daniela Reis Joaquim de Freitas

SUMÁRIO

CAPÍTULO 1..... 1

A TRAJETÓRIA DE JOAQUIM MONTEIRO CAMINHOÁ: UM BOTÂNICO NO IMPÉRIO DO BRASIL (1858-1896)

Alex Gonçalves Varela

 <https://doi.org/10.22533/at.ed.1472103111>

CAPÍTULO 2..... 20

ANÁLISE DE DESGASTE UTILIZANDO NANOLUBRIFICANTE ADITIVADO COM NANOPARTÍCULAS DE CELULOSE

Pollyana Grazielle Luz da Rocha


Matheus Gonçalves Leão de Oliveira

Paulo Vitor França Lemos

Larissa Alves de Sousa Costa

Adelson Ribeiro de Almeida Júnior

Jania Betania Alves da Silva

 <https://doi.org/10.22533/at.ed.1472103112>

CAPÍTULO 3..... 33

ANÁLISE TEMPORAL DA DISSEMINAÇÃO DE VEGETAÇÃO EXÓTICA EM DUNAS DO LITORAL MÉDIO DO RIO GRANDE DO SUL

Kátia Helena Lipp Nissinen

Jonas Marmitt Dias

Gustavo Machado Cauduro

 <https://doi.org/10.22533/at.ed.1472103113>

CAPÍTULO 4..... 43

CITOCOMPATIBILIDADE *IN VITRO* DE CÉLULAS-TRONCO MESENQUIMAIS EXPOSTAS À NANOTUBOS DE CARBONO MULTICAMADAS FUNCIONALIZADOS

Eduarda Rocha de Oliveira

Rafaella de Souza Salomão Zanette


Leonara Fayer

Elyabe Monteiro de Matos

Luiz Orlando Ladeira

Humberto de Mello Brandão

Michele Munk

 <https://doi.org/10.22533/at.ed.1472103114>


CAPÍTULO 5..... 51

QUALITY CONTROL OF ANTIVIRAL VACCINES WITH THE LITESIZER

Nathalie Etchart

Eduardo C. Araújo


Talita Cardeal

 <https://doi.org/10.22533/at.ed.1472103115>

CAPÍTULO 6..... 62

CYTOTOXIC AND GENOTOXIC EFFECTS OF THE GLUTARIMIDE ALKALOID JULOCROTINE


Regianne Maciel dos Santos Correa
Plínio Cerqueira dos Santos Cardoso
Lorena Araújo da Cunha
Tatiane Cristina Mota
Diego Di Felipe Ávila Alcantara
Giselle Maria Skelding Pinheiro Guilhon
Rosana de Nazaré Silva Peixoto
Rommel Rodriguez Burbano
Marcelo de Oliveira Bahia

 <https://doi.org/10.22533/at.ed.1472103116>

CAPÍTULO 7..... 74

ESTRUTURA E COMPOSIÇÃO FLORÍSTICA DO REMANESCENTE FLORESTAL DO CAMPUS DO CENTRO DE CIÊNCIAS AGRÁRIAS DA UNIVERSIDADE FEDERAL DE SÃO CARLOS (ARARAS, SP)


Steve de Oliveira Costa
Priscila Orlandini
Letícia Ribes de Lima

 <https://doi.org/10.22533/at.ed.1472103117>

CAPÍTULO 8..... 95

COMPARATIVE STUDY OF DRYING AND POST-FIXATION TECHNIQUES OF NIH 3T3 FIBROBLAST FOR SCANNING ELECTRON MICROSCOPY ANALYSIS


Susane Lopes
Giulia Galani Martha
Ana Paula Lorenzen Voytena
Deise Rebelo Consoni
Marcelo Maraschin

 <https://doi.org/10.22533/at.ed.1472103118>

CAPÍTULO 9..... 106

MULHERES ERVEIRAS DA AMAZÔNIA E O TURISMO DE BASE COMUNITÁRIA NA PERSPECTIVA DO DESENVOLVIMENTO LOCAL

Márcia Sueli Castelo Branco Bastos
Wagner Luiz Ramos Barbosa




 <https://doi.org/10.22533/at.ed.1472103119>

CAPÍTULO 10..... 123

PRÁCTICA DE RECOLECCIÓN DE LIANA “CIPÓ-TITICA” EN EL ESTADO DE AMAPÁ, BRASIL

Luciano Araujo Pereira
Patrick de Castro Cantuária

 <https://doi.org/10.22533/at.ed.14721031110>

CAPÍTULO 11	130
PRODUÇÃO DE NANOPARTÍCULAS DE PEJU/PPG PARA ENCAPSULAÇÃO DE DICLOFENACO DE SÓDIO	
Cassio Nazareno Silva da Silva	
Karla de Aleluia Batista	
 https://doi.org/10.22533/at.ed.14721031111	
CAPÍTULO 12	141
QUALIDADE MICROBIOLÓGICA DO SURURU (<i>MYTELLA FALCATA</i>) APERTIZADO EM SALMOURA ORIUNDO DA BAÍA DE SEPETIBA, RIO DE JANEIRO, BRASIL	
Karoline Ribeiro Palmeira Schmalz	
Flávia Aline Andrade Calixto	
Ronaldo Hertel	
Luiz Antonio Moura Keller	
Renata Torrezan	
Maria Carmela Kasnowski	
Eliana de Fátima Marques de Mesquita	
 https://doi.org/10.22533/at.ed.14721031112	
CAPÍTULO 13	151
QUESTÕES DE BIOLOGIA NO ENEM (2009-2019) E SUAS ABORDAGENS EM LIVROS DIDÁTICOS	
Vagner Dias Raimundo	
Orcione Aparecida Vieira Pereira	
Filipe Brum Machado	
 https://doi.org/10.22533/at.ed.14721031113	
SOBRE O ORGANIZADORA	163
ÍNDICE REMISSIVO	164

QUALITY CONTROL OF ANTIVIRAL VACCINES WITH THE LITESIZER

Data de aceite: 25/10/2021

Nathalie Etchart

Anton Paar GmbH

Eduardo C. Araújo

Anton Paar Brasil

Talita Cardeal

Anton Paar Brasil

ABSTRACT: The particle size of vaccines has a considerable influence on their half-life *in vivo*, as well as on their uptake by antigen-presenting cells. The surface charge of particles is also suspected of influencing the same parameters. Here we use DLS and ELS to characterize respectively the particle size and zeta potential of two inactivated antiviral vaccines.

KEYWORDS: DLS, ELS, particle size, zeta potential, pharmaceuticals, inactivated virus, vaccine adjuvants, aluminum salt, cold chain

CONTROLE DE QUALIDADE DE VACINAS ANTIVIRAIS UTILIZANDO DLS/ELS

RESUMO: O tamanho das partículas das vacinas tem uma influência considerável em sua meia-vida *in vivo*, bem como em sua absorção pelas células apresentadoras de antígenos. A carga superficial das partículas também é suspeita de influenciar os mesmos parâmetros. No artigo, utiliza-se DLS e ELS para caracterizar, respectivamente, o tamanho de partícula e o potencial zeta de duas

vacinas antivirais inativadas.

PALAVRAS - CHAVE: Vacina, DLS, ELS, tamanho de partículas, potencial zeta.

BACKGROUND

The particle size of vaccines has a considerable influence on their half-life *in vivo*, as well as on their uptake by antigen-presenting cells. The surface charge of particles is also suspected of influencing the same parameters. Here we use DLS and ELS to characterize respectively the particle size and zeta potential of two inactivated antiviral vaccines.

RESULTS

A tick-borne encephalitis (TBE) vaccine displays a monomodal particle size distribution in the lower micrometer range, corresponding to the expected size of the aluminum salt adjuvant. A cell-based influenza vaccine, in contrast, is shown to contain both split viruses (ca. 30 nm) and larger aggregates (ca. 250 nm). Zeta potential measurements indicate that both vaccines consist of weakly anionic particles. Interestingly, we demonstrate that simulated cold chain disruptions (heat treatment, freeze-thawing) induce significant changes in the particle size distribution of both vaccines.



1 | INTRODUCTION

Vaccines often constitute the only line of defense against viral infections, as the range of antiviral drugs currently available and treatment success are limited. The situation is different for bacterial infections, where antibiotics are an efficient therapeutic intervention.

Antiviral vaccines can consist of live-attenuated viral particles, which produce a low-noise infection in the recipient. While this strategy is able to mimic an infection by the pathogen very closely, and generally triggers a very robust immune response, it has the potential for serious side effects in immunocompromised individuals.

Thus, a majority of antiviral vaccines now consist in formulations which do not have the potential for replication in the host. These range from chemically inactivated whole or split viruses, to recombinant proteins or virus-like particles produced by genetic engineering. While these vaccines have a better safety profile, they also tend to trigger weaker immune responses than their live-attenuated counterparts.

Hence, many of them are administered together with so-called vaccine adjuvants, which increase the efficacy and longevity of the immune response.

The oldest and still most popular such adjuvant is aluminum salt (e.g., aluminum hydroxide or aluminum hydroxyphosphate). Its immunostimulatory properties are believed to be linked both to its capacity to adsorb and retain antigens for long periods at the site of injection, and to its ability to trigger the local release of pro-inflammatory mediators (1).

The particle size of a vaccine has a significant impact on its immunogenicity. With few exceptions, viruses are nanoparticles ranging in size from 15 to 300 nm. Upon injection, particles in this size range are efficiently taken up by dendritic cells, a class of sentinel cells uniquely endowed with the ability to induce both antibody- and killer cell-mediated immunity (2). In contrast, particles in the micrometer range, such as aluminum salt particles (1), are preferentially taken up by monocytes and macrophages, which predominantly induce an antibody-mediated immune response.

Bearing in mind that the distribution of the different classes of sentinel cells in the

body is strongly tissue- specific, a vaccine's particle size should therefore be tailored:

- Based on the type of immune response required to counter the pathogen, and
- Depending on the vaccine's delivery route (3).

Dynamic light scattering (DLS) is a fast and non- invasive measurement method which elucidates the size distribution of particles in the lower nanometer to lower micrometer size range. This makes DLS a method of choice for the quality control of antiviral vaccines (3).

Here we demonstrate the ability of the Litesizer to determine the particle size of two antiviral vaccines, an aluminum salt-adjuvanted, inactivated tick-borne encephalitis (TBE) vaccine, and a non-adjuvanted, inactivated and split influenza vaccine. We simulated cold chain disruptions by comparing samples stored in optimal conditions to samples that were heat-treated or submitted to a freeze-thaw cycle.

In addition, ELS measurements were performed to assess the zeta potential of the vaccine particles, giving additional clues on the stability of the preparations.

2 | EXPERIMENTAL SETUP

2.1 Samples

Two antiviral vaccines were purchased from a local pharmacy:

- TBE vaccine (FSME-Immun®, Pfizer, Austria)

Inactivated vaccine based on the Neudörfl strain of TBE. The virus is propagated in chicken embryo fibroblasts and inactivated by formaldehyde. Aluminum hydroxide is used as adjuvant, and human serum albumin as stabilizer. One dose consists of 2.4 μg of viral antigen in 0.5 mL of diluent (4).

- Influenza vaccine (Flucelvax®, Seqirus, USA) Quadrivalent influenza vaccine containing 2 strains of influenza A viruses and 2 strains of influenza B viruses, according to the WHO guidelines for the 2019-2020 northern hemisphere influenza season. The viruses are propagated in the continuous MDCK cell line, inactivated by b- propiolactone, detergent-disrupted and purified. One dose is formulated to contain 15 μg of viral hemagglutinin (HA) from every viral strain, or 60 μg total HA, in 0.5 mL (5).

2.2 Sample Treatment

Before treatment, the vaccines were stored in their original conditioning at +4 °C, according to manufacturer recommendations. Each sample was then split in 3 sub-samples in sterile microtubes, which were stored as follows:

- One sample was further stored at the optimal temperature of +4 °C (“Untreated” sample).
- One sample was stored in a dry oven set at 50 °C for 24 hrs., then returned to +4 °C (“Heat-treated” sample).
- One sample was frozen at -18 °C for 24 hrs., then thawed at +4 °C (“Freeze-thawed” sample).

All samples were tested in parallel, between 24 and 28 hrs. after collection from the original conditioning.

2.3 DLS Measurements

For DLS measurements, the TBE vaccine samples were diluted 1/10 in sterile saline solution (0.9 % NaCl). The influenza vaccine samples were diluted 1/5 in sterile saline. These dilutions were established as optimal for DLS measurements in a preliminary experiment (data not shown).

The measurements were performed on an Anton Paar Litesizer 500 instrument. Compared to disposable (polystyrene) cuvettes, quartz cuvettes display superior optical qualities and reduced protein adsorption, and were thus selected here.

Measurements were performed at 25 °C, in the 175° measurement angle (back angle), and using a manual quality mode (12 runs, 10 seconds per run). The optical filter and the focus position were selected automatically by the instrument.

Repetition series consisted in a minimum of 5 and a maximum of 8 consecutive measurements. Results were averaged over the whole measurement.

Statistical significance was established by standard t- test (two-sample, assuming unequal variance).

Differences between data sets were considered significant when the returned *P* value was < 0.05.

2.4 ELS measurements

Samples were analyzed in native, undiluted form, using the Univette and the low-volume accessory (sample volume: 50 μ L).

Zeta potential measurements were performed on a Litesizer 500 instrument at 25 °C, and using the Protein mode, which introduces small breaks between measurement runs and therefore limits Joule heating. The voltage was adjusted automatically by the instrument. The quality was set to the manual mode, with 200 runs per measurement.

Repetition series consisting in 5 consecutive measurements were performed.

3 | RESULTS AND DISCUSSION

3.1 Particle Size Measurement of TBE Vaccine Samples

As shown in Figure 1, the intensity-weighted particle size distribution of an optimally-stored TBE vaccine (“Untreated”, green curve) displays a single peak culminating between 2 and 3 μm . This is in accordance with the known particle size of commercial aluminum hydroxide used as vaccine adjuvant, which is in the lower micrometer range (1).

Furthermore, the particle size distribution of both mean curves (Figure 1) and of all individual measurements (not shown) is entirely devoid of peaks in the 0-to-1000 nm size range. This indicates that viral particles are not detectable as free-floating entities, and are likely overwhelmingly adsorbed onto the adjuvant particles.




Figure 1: Intensity-weighted particle size distributions of TBE vaccine samples, either untreated (green), heat-treated (red), or freeze-thawed (blue). Curves represent the averages from 5 to 8 consecutive measurements.

The particle size distributions of both freeze-thawed and heat-treated vaccine samples display monomodal distributions of slightly enlarged sizes (Figure 1). This is confirmed by the hydrodynamic diameter (HDD) results obtained for these samples (Table 1, Figure 2). Indeed, the mean HDD of the freeze-thawed sample is slightly but significantly increased compared to that of the untreated sample, from 3030 to 3582 nm ($P < 0.05$). The heat-treated sample displays a more pronounced increase in HDD, from 3030 to 4030 nm ($P < 0.01$).

Parameter	Untreated	Heat-treated	Freeze-thawed
HDD [nm]	3030	4030	3582
Standard deviation [nm]	157	511	277
Rel. standard deviation [%]	5.18	12.68	7.73

Table 1: Hydrodynamic diameter (HDD) results for untreated, heat- treated or freeze-thawed TBE vaccine samples. Averages from 5 to 8 consecutive measurements.




Figure 2: Hydrodynamic diameter results for untreated, heat- treated and freeze-thawed TBE vaccine samples. Statistical significance between the different data sets, as determined by standard t-test, is shown on the relevant brackets.

Of note, the standard deviation of the HDD for the heat-treated sample is much larger than that of the untreated sample (Figure 2). This sub-optimal reproducibility suggests that the Litesizer might be detecting very large aggregates in the heat-treated sample, which cannot be accurately represented as they are above the Litesizer detection limit of $10 \mu\text{m}$.

Taken together, these data indicate that the Litesizer is able to measure the particle size of an aluminum salt-adjuvanted viral vaccine. The detected particles are of the size expected for aluminum hydroxide.

Interestingly, a significant increase in HDD is observed for both heat-treated and freeze-thawed vaccine samples, indicating that major disruptions in the cold chain promote adjuvant aggregation.

3.2 Particle Size Measurement of Influenza Vaccine Samples

The expected size of the live influenza virus is around 100 nm, but inactivation and detergent splitting has been shown to reduce the size of the primary particles in vaccine preparations (6).

The particle size distribution of the untreated influenza vaccine sample shows a bimodal distribution, with a major peak culminating around 250 nm and a minor peak culminating around 30 nm (Figure 3, green curve). Thus, our results suggest that the

vaccine under study is composed of split viral particles of diameter around 30 nm, and of aggregates of larger sizes.




Figure 3: Intensity-weighted particle size distribution of influenza vaccine samples, either untreated (green), heat-treated (red), or freeze-thawed (blue). Curves represent the averages from 6 consecutive measurements.

Because large particles contribute much more strongly to the DLS signal than smaller ones, the fact that large particles visually dominate the distribution does not necessarily indicate that most of the material is in aggregated form. In fact, when the particle size distribution was switched from an intensity-weighted to a volume-based or a number-based one, the aggregate peak disappeared and only the minor peak (ca. 30 nm) was visible (data not shown). This indicates that the primary particles are much more numerous than the aggregates. However, since the DLS method is intrinsically intensity-weighted, and since the characterization of aggregates is highly relevant to the quality control of vaccines, we performed result analysis exclusively on the intensity-weighted data.

Figure 3 also reveals that both heat-treated and freeze-thawed preparations retain a bimodal profile, but that subtle differences in the size distribution arise from treatment. The heat-treated sample shows a major peak of decreased magnitude, and a minor peak of increased magnitude.

Interestingly, the freeze-thawed sample displays an opposite behavior, with a major peak of increased magnitude and a minor peak of decreased magnitude. This suggests that freeze-thawing tends to increase the aggregation of split virus particles, while heat treatment reduces it.

In addition to the HDD, which is calculated over the whole distribution, the Litesizer software calculates the mean diameter of particles contained in up to 3 individual peaks in the distribution. Furthermore, the area under the curve is calculated for every peak (Table 2), indicating the relative contribution of the particles in the relevant peaks to the DLS signal.

Parameter	Untreated	Heat-treated	Freeze-thawed
HDD \pm SD [nm]	156 \pm 2.2	151 \pm 4.4	164 \pm 3.3
Peak 1 by Intensity \pm SD [nm]	231 \pm 13.6	260 \pm 25.5	218 \pm 9.3
Peak 2 by Intensity \pm SD [nm]	34.2 \pm 3.8	42.3 \pm 5.4	29.4 \pm 2.6
Area under curve - Peak 1 \pm SD [%]	83.7 \pm 2.6	76.1 \pm 3.9	89.2 \pm 0.9
Area under curve - Peak 2 \pm SD [%]	16.3 \pm 2.6	23.9 \pm 3.9	10.8 \pm 0.9

Table 2: Hydrodynamic diameter (in nm), peak by intensity (in nm) and area under the curve – Peak (in %) for untreated, heat-treated and freeze-thawed influenza vaccine samples.

Results from the area under the curve for peak 1 (aggregates) and peak 2 (primary particles) confirm the differences between the samples observed in the particle size distribution. As shown in Figure 4, the contribution of primary particles (peak 2) to the DLS signal increases from 16 to 24 % when the sample is heat-treated ($P < 0.01$). Conversely, the primary particles only account for 11 % of the DLS signal in the freeze-thawed sample ($P < 0.001$).




Figure 4: Area under the curve for peak 2 (primary particles), by intensity, in %, for untreated, heat-treated and freeze-thawed influenza vaccine samples. Statistical significance between the different data sets, as determined by standard t-test, is shown on the relevant brackets.

These results indicate that subtle but significant differences in the relative proportion of primary particles and aggregates can be efficiently detected by DLS. Our observations also suggest that heat treatment and freeze-thawing have opposite effects on the aggregation behavior of inactivated influenza particles, with freeze-thawing promoting aggregation while

heat treatment leads to de-aggregation.

3.3 Zeta Potential Measurement of TBE and Influenza Vaccine Samples

The surface charge of particles, as measured by their zeta potential, is commonly used as indicator of colloidal stability. The larger the absolute zeta potential, the greater the repulsive forces between the particles are, and the more stable the preparation will be. But, in the case of particles destined for *in vivo* administration, it is also demonstrated that zeta potential influences particle uptake by specific cells.

On exosomes, negative charges have been shown to limit protein opsonization. This, in turn, slows down their clearance by the reticulo-endothelial system and increases their lifetime *in vivo* (7). Other reports indicate that cationic nanoparticles are preferentially taken up by dendritic cells, and result in increased local immune responses, compared to their anionic counterparts (8). In all, this suggests that the measurement of zeta potential is highly relevant to the quality control of vaccine preparations.

Here, the zeta potential of TBE samples (untreated, heat-treated or freeze-thawed) was measured with the Univette and its low-volume accessory, which enabled measurements with as little as 50 μL of sample.

As shown in Figure 5 and Table 3, the zeta potential of the TBE vaccine particles can be efficiently measured with the Litesizer, with good repeatability. The mean zeta potential appears weakly negative (ca. - 12 mV), and is not noticeably modified by heat treatment nor by freeze-thawing.




Figure 5: Representative Zeta potential distribution for an untreated TBE vaccine sample. Measurement performed with the Univette and the small volume accessory (sample volume = 50 μL).

Parameter	Untreated	Heat-treated	Freeze-thawed
Mean ZP	- 12.2 mV	- 11.5 mV	- 12 mV
Standard Deviation	1.3 mV	0.3 mV	0.2 mV
Rel. standard deviation	10.6 %	2.6 %	1.4 %

Table 3: Zeta potential results for untreated, heat-treated and freeze-thawed TBE vaccine samples. Mean results from 5 consecutive measurements.

The influenza vaccine sample also displays weakly negative (ca. - 6 mV) zeta potential values, which are also not significantly modified by heat treatment nor by freeze-thawing (Figure 6, Table 4).




Figure 6: Representative Zeta potential distribution for an untreated influenza vaccine sample. Measurement performed with the Univette and the small volume accessory (sample volume = 50 μ L).

Parameter	Untreated	Heat-treated	Freeze-thawed
Mean ZP	- 6.6 mV	- 6.0 mV	- 5.7 mV
Standard Deviation	0.9 mV	0.8 mV	1.3 mV
Rel. standard deviation	13.7 %	12.5 %	22.4 %

Table 4: Zeta potential results for untreated, heat-treated and freeze-thawed influenza vaccine samples. Mean results from 5 consecutive measurements.

As a rule of thumb, colloids are considered stable when absolute zeta potential values are over 30 mV. One can therefore speculate that the low zeta potential magnitude observed here for both vaccines accounts for their tendency to aggregate in response to cold chain disruptions.

4 | CONCLUSION

Both the size and the zeta potential of particles are relevant for the shelf life and immunogenicity of vaccine preparations. Here we demonstrate that the Litesizer is a quick and effective tool for the characterization of antiviral vaccines.

The TBE vaccine, which is adjuvanted with aluminum salt, is shown to consist of particles in the lower micrometer range, as expected from the literature. In the influenza vaccine, which is devoid of adjuvant, both split viruses and larger aggregates are observed. For both vaccines, simulated cold chain disruptions (heat treatment or freeze-thawing) are shown to trigger subtle but significant changes in the particle size distribution.

Zeta potential measurements were also successfully performed, demonstrating that both vaccines consist of weakly anionic particles. Cold chain disruptions do not appear to significantly modify the surface charge of the vaccine particles.

REFERENCES

1. **Shardlow E., Mold M. & Exley C. (2017).** From stock bottle to vaccine: elucidating the particle size distributions of aluminum adjuvants using dynamic light scattering. *Frontiers in Chemistry* 4:48.
2. **Etchart N., et al. (2001).** Dendritic cells recruitment and *in vivo* priming of CD8+ CTL induced by a single topical or transepithelial immunization via the buccal mucosa with measles virus nucleoprotein. *Journal of Immunology* 167:384-391.
3. **Slütter B. & Jiskoot W. (2016).** Sizing the optimal dimensions of a vaccine delivery: a particulate matter. *Expert Opinion on Drug Delivery* 13:167-170.
4. **World Health Organization (WHO) (2011).** Vaccines against tick-borne encephalitis: WHO position paper. *Weekly Epidemiological Record* 86:241-256.
5. **Lamb Y.N. (2019).** Cell-Based Quadrivalent Inactivated Influenza Virus Vaccine (Flucelvax® Tetra/Flucelvax Quadrivalent®): A Review in the Prevention of Influenza. *Drugs* . 2019, Bd. 79, S. 1337–1348.
6. **Kon T.C., et al. (2016).** Influenza Vaccine Manufacturing: Effect of Inactivation, Splitting and Site of Manufacturing. Comparison of Influenza Vaccine Production Processes. *PLOS One* 11:e0150700.
7. **Ren J., He W., Zheng L. & Duan H. (2016).** From structures to functions: insights into exosomes as promising drug delivery vehicles. *Biomaterials sciences* 4:910-921.
8. **Fromen C.A., et al. (2016).** Nanoparticle surface charge impacts distribution, uptake and lymph node trafficking by pulmonary antigen-presenting cells. *Nanomedicine* 12:677–687.

ÍNDICE REMISSIVO

A

Agroextractivismo 123
Amazônia Paraense 106, 107, 112
Aprendizagem 151, 153, 160, 162
Araceae 123, 124, 129
Áreas de preservação ambiental 33
Atlantic Forest 75

B

Baía de Sepetiba 6, 141, 144
Botânica 1, 2, 5, 18, 83, 87, 88, 91, 92, 94, 152, 156

C

Cadeia Produtiva Local 106, 107
Citotoxicidade 44, 63

D

Diclofenaco de sódio 6, 130, 131, 132, 134, 136, 137, 138

E

Encapsulação 6, 130, 132, 134, 136, 137, 138
Enlatamento 141, 144, 147
Ensaio do cometa 63
Espécies reativas de oxigênio 46, 48, 63

F

Fibroblastos 47, 48, 96
Forest Inventory 75

H

História das Ciências 1

I

Império do Brasil 4, 1, 2, 18, 19

J

Joaquim Monteiro Caminhoá 4, 1, 3, 18, 19
Julocrotina 63

L

Leishmaniose 63

Lianas 74, 78, 79, 86, 87, 89, 90, 123, 124, 125, 126, 127, 128

M

Microscopia eletrônica de varredura 96

Molusco 141, 142, 144, 149, 157

N

Nanolubrificantes 20, 21, 28, 29, 30

Nanopartículas de celulose 4, 20, 21, 22, 23, 24, 25, 26, 27, 28, 30

Nanossegurança 44

Nanotoxicidade 44, 45, 46

P

Pinus 33, 34, 35, 40, 41, 42

Plantas invasoras 33, 41

Plantas Medicinais 106, 107, 108, 112, 113, 114, 115, 118, 119, 120

Polipropilenoglicol 130, 131

Polissacarídeo de goma do cajueiro 130

S

Segurança Alimentar 141

Semi deciduous seasonal forest 75

Sensoriamento Remoto 33, 34, 41, 42

Surface charge of particles 51, 59


T

Taxa de desgaste 20, 23, 24, 27, 28, 29, 30

Técnicas de secagem e pós-fixação 96



www.atenaeditora.com.br 

contato@atenaeditora.com.br 

@atenaeditora 

www.facebook.com/atenaeditora.com.br 

AGENDA GLOBAL


DE PESQUISA

EM CIÊNCIAS

BIOLÓGICAS

 **Atena**
Editora

Ano 2021



www.atenaeditora.com.br 
contato@atenaeditora.com.br 
@atenaeditora 
www.facebook.com/atenaeditora.com.br 

AGENDA GLOBAL

DE PESQUISA

EM CIÊNCIAS

BIOLÓGICAS